WO2024126483 - IMPROVED LIPASE (GCL1) VARIANTS
National phase entry:
Publication Number
WO/2024/126483
Publication Date
20.06.2024
International Application No.
PCT/EP2023/085345
International Filing Date
12.12.2023
Title **
[English]
IMPROVED LIPASE (GCL1) VARIANTS
[French]
VARIANTS DE LIPASE GCL1 AMÉLIORÉS
Applicants **
NOVOZYMES A/S
Inventors
MALTEN, Marco
VIND, Jesper
DAMAGER, Iben
SANDSTRÖM, Anders, Gunnar
CHRISTENSEN, Lars, Lehmann, Hylling
Priority Data
22213319.1
14.12.2022
EP
23183807.9
06.07.2023
EP
23198169.7
19.09.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3262 | |
| EPO | Filing, Examination, Granting | 13108 | |
| Japan | Filing, Examination, Granting | 2192 | |
| South Korea | Filing, Examination, Granting | 2183 | |
| USA | Filing, Examination, Granting | 8040 |
Total:
28,785
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to lipase variants of a GCL1 lipase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.[French]
La présente invention concerne des variants d'une lipase GCL1. La présente invention concerne également des polynucléotides codant pour les variants ; des cellules hôtes, des vecteurs et des constructions d'acide nucléique comprenant les polynucléotides ; et des procédés d'utilisation des variants.